Genomic polymorphisms provide prognostic information in intermediate-risk acute myeloblastic leukemia

Area of Science:

• Genetics and Genomics
• Oncology
• Pharmacogenomics

Background:

• Current prognostic factors for acute myeloblastic leukemia (AML) are insufficient for predicting treatment response in intermediate-risk patients.
• Inherited functional genomic polymorphisms may contribute to the heterogeneous prognoses observed in AML.

Purpose of the Study:

• To identify germline polymorphisms associated with clinical outcomes in adult patients with intermediate-risk AML.
• To evaluate the prognostic value of genetic variations in drug metabolism, DNA repair, angiogenesis, and multidrug resistance genes.

Main Methods:

• Allelic discrimination method used to genotype polymorphisms in 110 adult intermediate-risk AML patients.
• Genes analyzed include GSTT1, SULT1C2, CDA, SXR, XPD, XPA, XPG, ERCC1, TOP2A, VEGF, and MDR1.
• Multivariate prognostic model adjusted for clinical and genetic factors to identify independent risk factors.

Main Results:

• XPA variant alleles were associated with an increased risk of refractoriness to chemotherapy (RR = 14; P = .02).
• Increased relapse risk was linked to SULT1C2 heterozygosity (RR = 4.1; P = .004), FLT3-ITD (RR 3.3; P = .003), and MDR1 variant alleles (RR = 2.4; P = .02).
• Adverse prognostic variables for overall survival included XPA (RR = 3.4; P = .02) and MDR1 (RR = 2.1; P = .02) variant alleles, and white blood cell (WBC) count (RR = 2.1; P = .02).

Conclusions:

• Germline polymorphisms in genes such as XPA and MDR1 are independent prognostic factors in intermediate-risk AML.
• These genetic markers can help refine risk stratification and guide treatment strategies for AML patients.
• Findings may aid in selecting risk-adapted treatment approaches for intermediate-risk AML.